New Derivatization Method for Quantitative Analysis of Δ⁹-THC-COOH in Urine

Significance of the topic

Accurate quantification of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (Δ9-THC-COOH) in urine is central to forensic toxicology, workplace drug testing and clinical research because it is the major inactive metabolite excreted after cannabis use. Routine LC–MS/MS assays typically require commercially produced stable isotope-labeled internal standards to correct for matrix effects and ensure quantitative accuracy. Supply-chain constraints and importation delays for those isotopically labeled standards can compromise laboratory throughput and method robustness. The described derivatization strategy provides a cost-effective approach to generate an isotopically labeled internal standard in-house, reducing dependency on external suppliers while maintaining analytical performance suitable for routine urine screening and quantitation.

Objectives and study overview

This Application News reports a derivatization-based workflow to quantify Δ9-THC-COOH in urine by LC–MS/MS using IPPAH (1‑isopropylpiperidine carboxylic acid hydrazide) and its deuterated analogue IPPAH‑d6. Key aims were to:

• Develop a simple synthesis for IPPAH and IPPAH‑d6 from inexpensive precursors (acetone/acetone‑d6),
• Derivatize Δ9‑THC‑COOH to form a stable, MS‑responsive adduct and to synthesize an internal standard (Δ9‑THC‑COOH‑IPPAH‑d6), and
• Validate analytical sensitivity, linearity, precision and derivatization efficiency in urine.

Methodology

Synthesis and derivatization:

• IPPAH and IPPAH‑d6 were synthesized from 4‑piperidinecarboxylic acid ethyl ester and acetone (or acetone‑d6) using sodium triacetoxyborohydride for reductive alkylation, followed by hydrazinolysis to install the hydrazide functionality. The procedure uses inexpensive reagents, liquid‑liquid extraction, vacuum concentration and simple workup to yield both labeled and unlabeled derivatizing agents.
• To produce the internal standard, Δ9‑THC‑COOH was reacted at room temperature with IPPAH‑d6 in the presence of the coupling reagent HSTU (N,N,N’,N’‑tetramethyl‑O‑(N‑succinimidyl)uronium hexafluorophosphate) for 30 minutes. The crude reaction solution was purified with a MonoSpin C18 spin column and reconstituted in methanol.

Urine sample pretreatment and derivatization:

• 100 µL urine was hydrolyzed with 10 µL 10 M NaOH at 50 °C for 15 min to cleave conjugates.
• Neutralization with 50 % trifluoroacetic acid (TFA) followed by protein precipitation with acetonitrile (1 mL), centrifugation, evaporation to dryness and reconstitution in MeOH.
• Internal standard (Δ9‑THC‑COOH‑IPPAH‑d6), IPPAH derivatizing agent and 100 mM HSTU in ACN were added; reaction proceeded 30 min at room temperature. Following acidification, samples were cleaned on MonoSpin C18 and reconstituted in 50 % MeOH for LC–MS/MS.

LC–MS/MS conditions:

• Instrumentation: Nexera XR UHPLC coupled to LCMS‑8050 triple quadrupole MS (positive ESI).
• Column: Raptor ARC‑18 (100 × 3.0 mm, 1.8 µm) at 40 °C; injection 2 µL.
• Mobile phases: A = 10 mM ammonium formate + 0.1 % formic acid (aqueous); B = 10 mM ammonium formate in 90 % MeOH + 0.1 % formic acid.
• Flow 0.4 mL/min with a gradient ramping %B from 75 % (0–9 min) to 85 % (12–18 min) then down to 30 % (18–23 min).
• MS settings: nebulizer gas 3 L/min, drying gas 5 L/min, heating gas 15 L/min, DL 150 °C, heat block 300 °C, interface 400 °C.
• MRM transitions: Δ9‑THC‑COOH‑IPPAH quantifier 512.15 > 154.15 (CE −31 V) with confirmatory transitions 512.15 > 193.10 and 512.15 > 299.20; Δ9‑THC‑COOH‑IPPAH‑d6 quantifier 518.00 > 160.10 (CE −32 V) with matching confirmatory transitions.

Used Instrumentation

Reported instruments and consumables:

• Shimadzu Nexera XR UHPLC.
• Shimadzu LCMS‑8050 triple quadrupole mass spectrometer (positive ESI).
• Raptor ARC‑18 analytical column (100 × 3.0 mm, 1.8 µm; Restek P/N 931421E).
• MonoSpin C18 spin columns (GL Sciences) for reaction cleanup and concentration.
• Reagents: IPPAH and IPPAH‑d6 (synthesized in‑house), HSTU coupling reagent, sodium triacetoxyborohydride, hydrazine, acetonitrile, methanol, formic acid, ammonium formate, TFA.

Main results and discussion

Analytical performance:

• Linearity: Calibration range 1–500 ng/mL with correlation coefficient R ≥ 0.998 (weighted 1/C regression). The method produced a reliable calibration curve across this dynamic range.
• Sensitivity: Clear detection at 5 ng/mL and a lower limit of quantitation reported at 1 ng/mL or lower.
• Precision and accuracy: Intra‑day repeatability (n = 5) at 15 ng/mL (low) gave mean measured concentration 13.2 ng/mL (accuracy 87.7 %, %RSD 5.7). At 200 ng/mL (high) the mean was 200 ng/mL (accuracy 100 %, %RSD 6.4).
• Derivatization efficiency: Analysis of the highest calibration standard (500 ng/mL) showed that unreacted native Δ9‑THC‑COOH was below the LLOQ (<1 ng/mL), indicating derivatization efficiency ≥ 99 % under the described conditions.

Interpretation: The in‑house synthesis of a deuterated derivatizing agent and its use to prepare an isotopically labeled analyte adduct produced a robust internal standard that compensates for matrix effects and sample handling. The approach produced adequate sensitivity and precision for forensic and clinical cutoffs, while reducing dependency on commercial isotope suppliers.

Benefits and practical applications

Practical advantages:

• Supply‑chain resilience: Generating IPPAH‑d6 and preparing Δ9‑THC‑COOH‑IPPAH‑d6 in‑lab reduces reliance on imported isotopic standards and mitigates procurement delays or export/import restrictions.
• Cost efficiency: Starting materials (acetone/acetone‑d6, 4‑piperidinecarboxylic acid ethyl ester) and straightforward synthetic steps lower per‑assay reagent cost compared with purchasing commercial labeled standards.
• Analytical performance: High derivatization yield, low LLOQ and acceptable precision make the method suitable for urine drug testing workflows and forensic applications where Δ9‑THC‑COOH monitoring is required.

Future trends and potential applications

Potential developments and broader uses:

• Extension to other carboxylic acid analytes: The IPPAH‑type hydrazide strategy and isotope‑coded derivatization can be adapted for accurate quantitation of other endogenous or xenobiotic carboxylic acids (including marine toxins, pharmaceuticals and metabolites).
• Automation and scale‑up: Integration of derivatization and solid‑phase cleanup into automated sample preparation platforms or 96‑well spin plate workflows could increase throughput for high‑volume forensic and clinical laboratories.
• Regulatory adoption and inter‑laboratory harmonization: Multi‑site validation and ring trials would support wider acceptance for compliance testing and forensic standards development.
• Direct analysis of conjugates: Additional optimization to include on‑column or enzymatic hydrolysis steps could simplify workflows for glucuronide forms of THC metabolites.
• Alternative stable‑isotope sources: Similar syntheses using 13C or 15N labeled precursors could be explored to broaden isotope‑label options beyond deuterium.

Conclusion

The described derivatization protocol using IPPAH and IPPAH‑d6 provides a pragmatic route to synthesize a matched isotopically labeled internal standard (Δ9‑THC‑COOH‑IPPAH‑d6) and to derivatize urine Δ9‑THC‑COOH for LC–MS/MS quantitation. The method demonstrates excellent derivatization yield (≥99 %), a low LLOQ (≤1 ng/mL), strong linearity (1–500 ng/mL, R ≥ 0.998) and acceptable intra‑day precision and accuracy at forensic cutoff concentrations. By enabling in‑house production of an isotope‑coded internal standard from inexpensive precursors, the workflow can enhance laboratory autonomy, reduce costs and preserve analytical quality for forensic and clinical cannabinoid testing.

Reference

1. Kawasue S., Kuniyoshi K., et al (2026) Novel isotope-coded derivatization of carboxylic acids provides accurate quantification of Azaspiracids in shellfish by liquid chromatography–tandem mass spectrometry, Journal of Chromatography B, 1267, 124826.